Article Figures & Data
Figures
- Figure 1.
Change in LDL-C from Baseline to Week 12.
ANCOVA=analysis of covariance; Q4W=every 4 weeks; SE=standard error; UC=ultracentrifugation. LDL-C values at baseline and Week 12 were measured using preparative UC. Least Square Means are presented from the ANCOVA model including treatment and stratification factors as covariates. Missing UC LDL-C values at Week 12 were imputed using last observation carried forward and calculated LDL-C. A Hochberg adjustment was used to control the family wise error rate at ≤0.05.
Reproduced with permission from F Raal, MD.
- Figure 2.
Percentage of Patients Achieving LDL-C Targets by Week 12.
LDL-C=low-density lipoprotein; Q4W=every 4 weeks.
Reproduced with permission from F Raal, MD.
- Figure 3.
Percent Change in LDL-C from Baseline at Week 12.
Q4W=every 4 weeks; SE=stantard error.
Reproduced with permission from E Stein, MD, PhD.
- Figure 4.
Primary Endpoint: AMG 145 Reduced LDL-C at 12 Weeks.
LDL-C=low-density lipoprotein cholesterol; Q2W=every 2 weeks. SE=standard error. p<0.0001 for each dose vs placebo.
Reproduced with permission from RP Giugliano, MD.
- Figure 5.
Secondary Results at 12 Weeks with Top Two AMG 145 Doses.
LDL-C=low-density lipoprotein cholesterol; HDL-C=high-density lipoprotein cholesterol; VLDL-C=very-low-density lipoprotein cholesterol; Q4W=every 4 weeks. p<0.0001 versus placebo for all parameters.
Reproduced with permission from RP Giugliano, MD.
- Figure 6.
Effects of AMG 145 Versus Placebo and Ezetimibe on LDL-C.
LDL-C=low-density lipoprotein cholesterol; Q2W=every 2 weeks; Q4W=every 4 weeks; QD=every day; SE=standard error.
Adapted from MJ Koren, MD. AHA 2012.
Tools
Human Monoclonal Antibody for PCSK9 Lowers Cholesterol and Is Well Tolerated
Permalink:
Table of contents
Cited By...
- No citing articles found.